Prospective study of clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates

Clinical Microbiology and Infection

Volumn 13, Issue 11, 2007, Pages 1048-1057

  Barbut, Frederic ^a   Mastrantonio, P ^b   Delmee M ^c   Brazier, J ^d   Kuijper, E ^e   Poxton, I ^f   Ackermann, G ^g   Bouza, E ^g   Balmelli, C ^g   Drudy, D ^g   Ladas, H ^g   Nagy, E ^g   Pituch, H ^g   Wullt, M ^g   Yucesoy M ^g   Rupnik, M ^g  

^a HÔPITAL SAINT ANTOINE   (France)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g NONE

Author keywords

Antimicrobial susceptibility; Clostridium difficile; Epidemiology; European study; PCR ribotyping; Toxinotyping

Indexed keywords

CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE TOXIN C; CLOSTRIDIUM TOXIN; ERYTHROMYCIN; METRONIDAZOLE; MOXIFLOXACIN; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DISEASE SURVEILLANCE; EPIDEMIC; EUROPE; FEMALE; GENE CLUSTER; GENE DELETION; GENOTYPE; HUMAN; INCIDENCE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STRAIN DIFFERENCE;

CLOSTRIDIUM DIFFICILE;

EID: 35048865459     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01824.x     Document Type: Article

References (49)

1. Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978; 75: 778-782.
2. Larson HE, Price AB, Honour P, Borriello SP. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1978; i: 1063-1066.
3. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-262.
4. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320: 204-210.
5. Barbut F, Mario N, Meyohas MC, Binet D, Frottier J, Petit JC. Investigation of a nosocomial outbreak of Clostridium difficile -associated diarrhoea among AIDS patients by random amplified polymorphic DNA (RAPD) assay. J Hosp Infect 1994; 26: 181-189.
6. Cartmill TD, Panigrahi H, Worsley MA, McCann DC, Nice CN, Keith E. Management and control of a large outbreak of diarrhoea due to Clostridium difficile. J Hosp Infect 1994; 27: 1-15.
7. Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficile -associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26: 273-280.
8. Voth DE, Ballard JD. Clostridium difficile toxins: Mechanism of action and role in disease. Clin Microbiol Rev 2005; 18: 247-263.
9. Popoff MR, Rubin EJ, Gill DM, Boquet P. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun 1988; 56: 2299-2306.
10. Perelle S, Gibert M, Bourlioux P, Corthier G, Popoff MR. Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196. Infect Immun 1997; 65: 1402-1407.
11. Geric B, Rupnik M, Gerding DN, Grabnar M, Johnson S. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol 2004; 53: 887-894.
12. Goncalves C, Decre D, Barbut F, Burghoffer B, Petit JC. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol 2004; 42: 1933-1939.
13. Pituch H, Rupnik M, Obuch-Woszczatynski P, Grubesic A, Meisel-Mikolajczyk F, Luczak M. Detection of binary-toxin genes (cdtA and cdtB) among Clostridium difficile strains isolated from patients with C. difficile -associated diarrhoea (CDAD) in Poland. J Med Microbiol 2005; 54: 143-147.
14. Rupnik M, Kato N, Grabnar M, Kato H. New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia. J Clin Microbiol 2003; 41: 1118-1125.
15. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile -associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-2449.
16. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-2441.
17. Pepin J, Valiquette L, Alary ME et al. Clostridium difficile -associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. Can Med Assoc J 1991; 171: 466-472.
18. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile -associated disease during an epidemic caused by a hypervirulent strain in Quebec. Can Med Assoc J 2005; 173: 1037-1042.
19. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in north America and Europe. Lancet 2005; 366: 1079-1084.
20. MacCannell DR, Louie TJ, Gregson DB et al. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from eastern and western Canada. J Clin Microbiol 2006; 44: 2147-2152.
21. Joseph R, Demeyer D, Vanrenterghem D, van den Berg R, Kuijper E, Delmée M. First isolation of Clostridium difficile PCR ribotype 027, toxinotype III in Belgium. Euro Surveill 2005; 10: E051020-E051024.
22. Kuijper EJ, Van den Berg RJ, Debast S et al. Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerg Infect Dis, 2006; 12: 827-830.
23. Tachon M, Cattoen C, Blanckaert K et al. First cluster of C. difficile toxinotype III, PCR-ribotype 027 associated disease in France: preliminary report. Euro Surveill 2006; 11: E060504.1.
24. Delmée M, Thonnard J. Clostridium difficile toxin A detection on colonies. Clin Microbiol Infect 1997; 3: 389-390.
25. Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B, Popoff M. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000; 186: 307-312.
26. Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmée M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 1998; 36: 2240-2247.
27. Rupnik M. How to detect Clostridium difficile variant strains in a routine laboratory. Clin Microbiol Infect 2001; 7: 417-420.
28. Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (tcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 2002; 40: 3470-3475.
29. Stubbs SL, Brazier JS, O'Neill GL, Duerden BI. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999; 37: 461-463.
30. Barbut F, Delmée M, Brazier JS et al. A European survey of diagnostic methods and testing protocols for Clostridium difficile. Clin Microbiol Infect 2003; 9: 989-996.
31. Sohn S, Climo M, Diekema D et al. Varying rates of Clostridium difficile -associated diarrhea at prevention epicenter hospitals. Infect Control Hosp Epidemiol 2005; 26: 676-679.
32. Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis 2004; 189: 1585-1589.
33. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile -associated disease in North America and Europe. Clin Microbiol Infect 2006; 12 (suppl 6): 2-18.
34. Pituch H, van Leeuwen W, Maquelin K et al. Toxin profiles and resistances to macrolides and newer fluoroquinolones as epidemicity determinants of clinical isolates of Clostridium difficile from Warsaw, Poland. J Clin Microbiol 2007; 45: 1607-1610.
35. National Clostridium difficile Standards Group. Report to the Department of Health. J Hosp Infect 2004; 56 (suppl 1): 1-38.
36. Delmée M, Ramboer I, Van Broeck J, Suetens C. Epidemiology of Clostridium difficile toxinotype III, PCR-ribotype 027 associated disease in Belgium, 2006. Euro Surveill 2006; 11: E060914.2.
37. Coignard B, Barbut F, Blanckaert K et al. Emergence of Clostridium difficile toxinotype III, PCR-ribotype 027-associated disease, France, 2006. Euro Surveill 2006; 11: E060914.1.
38. Bourgault AM, Lamothe F, Loo VG, Poirier L. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Quebec, Canada. Antimicrob Agents Chemother 2006; 50: 3473-3475.
39. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 7th edn. Wayne, PA: CLSI, 2007.
40. Drudy D, Kyne L, O'Mahony D, Fanning S. GyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027. Emerg Infect Dis 2007; 13: 504-505.
41. Barbut F, DecréD, Lalande V et al. Clinical features of Clostridium difficile -associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol 2005; 54: 181-185.
42. Barbut F, Gariazzo B, Bonne L et al. Clinical features of Clostridium difficile -associated infections and molecular characterization of strains: Results of a retrospective study, 2000-2004. Infect Control Hosp Epidemiol 2007; 28: 131-139.
43. Geric B, Carman RJ, Rupnik M et al. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis 2006; 193: 1143-1150.
44. Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40: 1586-1590.
45. Pepin J, Alary ME, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 1591-1597.
46. Ackermann G, Degner A, Cohen SH, Silva J, Rodloff AC. Prevalence and association of macrolide-lincosamide-streptogramin B (MLS(b)) resistance with resistance to moxifloxacin in Clostridium difficile. J Antimicrob Chemother 2003; 51: 599-603.
47. Dridi L, Tankovic J, Burghoffer B, Barbut F, Petit JC. gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother 2002; 46: 3418-3421.
48. Ackermann G, Tang-Feldman YJ, Schaumann R et al. Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile. Clin Microbiol Infect 2003; 9: 526-530.
49. Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile -associated diarrhea: A cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-1260.